What is the CVR number of LAB57 ApS?

LAB57 ApS is registered with CVR / Virk under CVR 41328932.

What is the revenue of LAB57 ApS?

LAB57 ApS reported revenue of DKK -22K in 2024.

Who is the CEO of LAB57 ApS?

John Hyltoft is Chief Executive Officer of LAB57 ApS, in role since 2020.

Who is the chairman of LAB57 ApS?

Martin Thisted chairs the board of LAB57 ApS, in role since 2020.

Where is LAB57 ApS headquartered?

LAB57 ApS's registered address is K. Christensens Vej 6, 1. tv.

LAB57 ApS

APSActive

CVR 41328932K. Christensens Vej 6, 1. tvRetail sale of pharmaceutical products · NACE 4773Est. 2020— employeeswww.lab57.dk

Full Risika report

Revenue 2024

DKK -22K

+202% vs 2023

EBITDA margin

100.0%

-202% vs 2023

Equity ratio

-23.7%

Financial strength

Net profit 2024

DKK -22K

-243% vs 2023

EBITDA — year on yearDKK millions

Key figuresAnnual report 2024

Revenue	DKK -22K	+202%
EBITDA	DKK -22K	-202%
Net profit	DKK -22K	-243%
Total assets	DKK 69K	-25%
Equity	DKK -16K	-383%
Employees	—	—

Item	2020	2021	2022	2023	2024
Revenue	43	-77	-23	-7	-22
Staff expenses	-0	-0	-0	-0	-0
EBITDA	43	-77	-23	-7	-22
Depreciation & amort.	-0	-0	-0	-0	-0
EBIT	43	-77	-23	-7	-22
Net financials	-1	-1	-1	23	-0
Profit before tax	42	-79	-25	16	-22
Tax	9	-17	-5	23	-0
Net profit	33	-61	-19	-6	-22

Item	2020	2021	2022	2023	2024
Total assets	153	103	118	91	69
Equity	73	12	12	6	-16
Long-term debt	0	0	0	0	0
Short-term debt	80	92	106	86	85
Total debt	80	92	106	86	85

Name	Role	Member since	Age	Other directorships
JH John Hyltoft Chief Executive Officer	Chief Executive Officer	2020	—	—

Name	Role	Member since	Age	Other directorships
MT Martin Thisted	Chairman	2020	—	—

Shareholder	Type	Ownership	Votes	Since
KEY LEARNING A/S	Company	33.3%	33.3%	2022
John Hyltoft Holding ApS	Company	33.3%	33.3%	2022
Biogen Holding ApS	Company	33.3%	33.3%	2022

Person	Role here	Other companies
John Hyltoft	Chief Executive Officer	0 companies
Martin Thisted	Chairman	0 companies

LAB57 ApS

APSActive

CVR 41328932K. Christensens Vej 6, 1. tvRetail sale of pharmaceutical products · NACE 4773Est. 2020— employeeswww.lab57.dk

Full Risika report

Revenue 2024

DKK -22K

+202% vs 2023

EBITDA margin

100.0%

-202% vs 2023

Equity ratio

-23.7%

Financial strength

Net profit 2024

DKK -22K

-243% vs 2023

EBITDA — year on yearDKK millions

Key figuresAnnual report 2024

Revenue	DKK -22K	+202%
EBITDA	DKK -22K	-202%
Net profit	DKK -22K	-243%
Total assets	DKK 69K	-25%
Equity	DKK -16K	-383%
Employees	—	—